{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:16:52Z","timestamp":1768166212270,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The purpose of this study is to compare and analyze the clinicopathological characteristics and prognosis of patients with invasive ductal carcinoma coexisting with ductal carcinoma in situ (IDC-DCIS) and invasive ductal carcinoma (IDC) in triple-negative breast cancer (TNBC), and to explore the factors affecting the prognosis, so as to provide new ideas for clinical diagnosis and treatment of these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The patients with TNBC underwent surgery in the Department of Breast Surgery of Harbin Medical University Cancer Hospital from October 2012 to December 2018 were retrospectively analyzed and divided into IDC-DCIS group and IDC group. The clinicopathological characteristics and prognosis of the two groups were compared. P\u2009&lt;\u20090.05 was considered statistically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 358 patients were enrolled. There were significant differences in age (P\u2009=\u20090.002), family history (P\u2009=\u20090.016), menopausal status (P\u2009=\u20090.003), KI-67% (P\u2009&lt;\u20090.001), lymphovascular invasion (P\u2009=\u20090.010), histologic grade of IDC (P\u2009&lt;\u20090.001) and multifocal (P\u2009&lt;\u20090.001) between the two groups. The disease-free survival (DFS) of the IDC-DCIS group was better than that of the IDC group (the 5-year DFS was 87.9% vs. 82.6%, P\u2009=\u20090.045), but the overall survival (OS) of the two groups was not statistically significant (the 5-year OS was 96.2% vs. 96.0%, P\u2009=\u20090.573). In addition, the coexistence of DCIS (P\u2009=\u20090.030), lymph node pathologic stage (P\u2009=\u20090.001), tumor location (P\u2009=\u20090.011), and adjuvant chemotherapy (P\u2009&lt;\u20090.001) were independent prognostic factors for DFS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In TNBC, the IDC-DCIS group had less invasive biological characteristics. The DFS of the IDC-DCIS group was better than that of the IDC group, but there was no statistical difference in OS between the two groups. In addition, the coexistence of DCIS, lymph node stage, tumor location and adjuvant chemotherapy may be independent prognostic factors for DFS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-04895-9","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T12:16:58Z","timestamp":1687609018000},"page":"11181-11191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ"],"prefix":"10.1007","volume":"149","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,24]]},"reference":[{"key":"4895_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"4895_CR2","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1038\/s41388-019-0765-y","volume":"38","author":"L Bu","year":"2019","unstructured":"Bu L, Baba H, Yoshida N, Miyake K, Yasuda T, Uchihara T, Tan P, Ishimoto T (2019) Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene 38:4887\u20134901. https:\/\/doi.org\/10.1038\/s41388-019-0765-y","journal-title":"Oncogene"},{"key":"4895_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12282-011-0330-1","volume":"20","author":"P Carabias-Meseguer","year":"2013","unstructured":"Carabias-Meseguer P, Zapardiel I, Cusid\u00f3-Gimferrer M, Godoy-Tundidor S, Tresserra-Casas F, Rodriguez-Garc\u00eda I, F\u00e1bregas-Xaurad\u00f3 R, Xercavins-Montosa J (2013) Influence of the in situ component in 389 infiltrating ductal breast carcinomas. Breast Cancer 20:213\u2013217. https:\/\/doi.org\/10.1007\/s12282-011-0330-1","journal-title":"Breast Cancer"},{"key":"4895_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/path.4840","volume":"241","author":"AK Casasent","year":"2017","unstructured":"Casasent AK, Edgerton M, Navin NE (2017) Genome evolution in ductal carcinoma in situ: invasion of the clones. J Pathol 241:208\u2013218. https:\/\/doi.org\/10.1002\/path.4840","journal-title":"J Pathol"},{"key":"4895_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2017.12.007","volume":"172","author":"AK Casasent","year":"2018","unstructured":"Casasent AK, Schalck A, Gao R, Sei E, Long A, Pangburn W, Casasent T, Meric-Bernstam F, Edgerton ME, Navin NE (2018) Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell 172:205-217.e12. https:\/\/doi.org\/10.1016\/j.cell.2017.12.007","journal-title":"Cell"},{"key":"4895_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.21037\/atm.2019.08.16","volume":"7","author":"H Chen","year":"2019","unstructured":"Chen H, Bai F, Wang M, Zhang M, Zhang P, Wu K (2019a) The prognostic significance of co-existence ductal carcinoma in situ in invasive ductal breast cancer: a large population-based study and a matched case-control analysis. Ann Transl Med 7:484. https:\/\/doi.org\/10.21037\/atm.2019.08.16","journal-title":"Ann Transl Med"},{"key":"4895_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05272-2","volume":"177","author":"XY Chen","year":"2019","unstructured":"Chen XY, Yeong J, Thike AA, Bay BH, Tan PH (2019b) Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res Treat 177:17\u201327. https:\/\/doi.org\/10.1007\/s10549-019-05272-2","journal-title":"Breast Cancer Res Treat"},{"key":"4895_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/PAI.0000000000001028","volume":"30","author":"MM Dawoud","year":"2022","unstructured":"Dawoud MM, Jones DT, Chelala C, Abdou AG, Dreger SA, Asaad N, Abd El-Wahed M, Jones L (2022) Expression profile of myoepithelial cells in DCIS: do they change from protective angels to wicked witches. Appl Immunohistochem Mol Morphol 30:397\u2013409. https:\/\/doi.org\/10.1097\/PAI.0000000000001028","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"4895_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10911-018-9414-2","volume":"23","author":"RS DeVaux","year":"2018","unstructured":"DeVaux RS, Herschkowitz JI (2018) Beyond DNA: the role of epigenetics in the premalignant progression of breast cancer. J Mammary Gland Biol Neoplasia 23:223\u2013235. https:\/\/doi.org\/10.1007\/s10911-018-9414-2","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"4895_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41523-020-0157-z","volume":"6","author":"HS Elsarraj","year":"2020","unstructured":"Elsarraj HS, Hong Y, Limback D, Zhao R, Berger J, Bishop SC, Sabbagh A, Oppenheimer L, Harper HE, Tsimelzon A, Huang S, Hilsenbeck SG, Edwards DP, Fontes J, Fan F, Madan R, Fangman B, Ellis A, Tawfik O, Persons DL, Fields T, Godwin AK, Hagan CR, Swenson-Fields K, Coarfa C, Thompson J, Behbod F (2020) BCL9\/STAT3 regulation of transcriptional enhancer networks promote DCIS progression. NPJ Breast Cancer 6:12. https:\/\/doi.org\/10.1038\/s41523-020-0157-z","journal-title":"NPJ Breast Cancer"},{"key":"4895_CR11","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.humpath.2012.09.022","volume":"44","author":"MP Foschini","year":"2013","unstructured":"Foschini MP, Morandi L, Leonardi E, Flamminio F, Ishikawa Y, Masetti R, Eusebi V (2013) Genetic clonal mapping of in situ and invasive ductal carcinoma indicates the field cancerization phenomenon in the breast. Hum Pathol 44:1310\u20131319. https:\/\/doi.org\/10.1016\/j.humpath.2012.09.022","journal-title":"Hum Pathol"},{"key":"4895_CR12","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"key":"4895_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1158\/2326-6066.CIR-19-0786","volume":"8","author":"CR Gil Del Alcazar","year":"2020","unstructured":"Gil Del Alcazar CR, Ale\u010dkovi\u0107 M, Polyak K (2020) Immune Escape during Breast Tumor Progression. Cancer Immunol Res 8:422\u2013427. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0786","journal-title":"Cancer Immunol Res"},{"key":"4895_CR14","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00432-019-02930-2","volume":"145","author":"CW Goh","year":"2019","unstructured":"Goh CW, Wu J, Ding S, Lin C, Chen X, Huang O, Chen W, Li Y, Shen K, Zhu L (2019) Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC\/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. J Cancer Res Clin Oncol 145:1877\u20131886. https:\/\/doi.org\/10.1007\/s00432-019-02930-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"4895_CR15","doi-asserted-by":"publisher","unstructured":"Guan X, Xu G, Shi A, Zou Y, Zhan Y, Fan Z, Dong Y (2020) Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study. Medicine (Baltimore) 99:e23487. doi:https:\/\/doi.org\/10.1097\/MD.0000000000023487","DOI":"10.1097\/MD.0000000000023487"},{"key":"4895_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.breast.2008.10.004","volume":"18","author":"UW Jayasinghe","year":"2009","unstructured":"Jayasinghe UW, Boyages J (2009) Tumour location is not an independent prognostic factor for survival following a diagnosis of breast cancer. Breast 18:41\u201346. https:\/\/doi.org\/10.1016\/j.breast.2008.10.004","journal-title":"Breast"},{"key":"4895_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13148-015-0094-0","volume":"7","author":"KC Johnson","year":"2015","unstructured":"Johnson KC, Koestler DC, Fleischer T, Chen P, Jenson EG, Marotti JD, Onega T, Kristensen VN, Christensen BC (2015) DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer. Clin Epigenetics 7:75. https:\/\/doi.org\/10.1186\/s13148-015-0094-0","journal-title":"Clin Epigenetics"},{"key":"4895_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-020-01267-w","volume":"22","author":"M Kim","year":"2020","unstructured":"Kim M, Chung YR, Kim HJ, Woo JW, Ahn S, Park SY (2020) Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res 22:32. https:\/\/doi.org\/10.1186\/s13058-020-01267-w","journal-title":"Breast Cancer Res"},{"key":"4895_CR19","doi-asserted-by":"publisher","first-page":"18007","DOI":"10.1038\/s41598-021-97390-5","volume":"11","author":"M Kim","year":"2021","unstructured":"Kim M, Choi HY, Woo JW, Chung YR, Park SY (2021) Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast. Sci Rep 11:18007. https:\/\/doi.org\/10.1038\/s41598-021-97390-5","journal-title":"Sci Rep"},{"key":"4895_CR20","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","volume":"9","author":"AJ Kole","year":"2019","unstructured":"Kole AJ, Park HS, Johnson SB, Kelly JR, Moran MS, Patel AA (2019) Overall survival is improved when DCIS accompanies invasive breast cancer. Sci Rep 9:9934. https:\/\/doi.org\/10.1038\/s41598-019-46309-2","journal-title":"Sci Rep"},{"key":"4895_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.11116","volume":"105","author":"N Kroman","year":"2003","unstructured":"Kroman N, Wohlfahrt J, Mouridsen HT, Melbye M (2003) Influence of tumor location on breast cancer prognosis. Int J Cancer 105:542\u2013545. https:\/\/doi.org\/10.1002\/ijc.11116","journal-title":"Int J Cancer"},{"key":"4895_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/tbj.12359","volume":"21","author":"MD Lagios","year":"2015","unstructured":"Lagios MD, Silverstein MJ (2015) Ductal carcinoma in situ: recent history and areas of controversy. Breast J 21:21\u201326. https:\/\/doi.org\/10.1111\/tbj.12359","journal-title":"Breast J"},{"key":"4895_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2013.06.006","volume":"40","author":"SW Lam","year":"2014","unstructured":"Lam SW, Jimenez CR, Boven E (2014) Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat Rev 40:129\u2013138. https:\/\/doi.org\/10.1016\/j.ctrv.2013.06.006","journal-title":"Cancer Treat Rev"},{"key":"4895_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijsu.2019.01.016","volume":"63","author":"S Lopez Gordo","year":"2019","unstructured":"Lopez Gordo S, Blanch Falp J, Lopez-Gordo E, Just Roig E, Encinas Mendez J, Seco Calvo J (2019) Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study. Int J Surg 63:98\u2013106. https:\/\/doi.org\/10.1016\/j.ijsu.2019.01.016","journal-title":"Int J Surg"},{"key":"4895_CR25","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.1158\/0008-5472.CAN-08-2660","volume":"70","author":"A Miron","year":"2010","unstructured":"Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K (2010) PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 70:5674\u20135678. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2660","journal-title":"Cancer Res"},{"key":"4895_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13058-021-01494-9","volume":"23","author":"A Niwi\u0144ska","year":"2021","unstructured":"Niwi\u0144ska A, Olszewski WP (2021) The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer. Breast Cancer Res 23:118. https:\/\/doi.org\/10.1186\/s13058-021-01494-9","journal-title":"Breast Cancer Res"},{"key":"4895_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/his.12796","volume":"68","author":"JM Pang","year":"2016","unstructured":"Pang JM, Gorringe KL, Fox SB (2016) Ductal carcinoma in situ - update on risk assessment and management. Histopathology 68:96\u2013109. https:\/\/doi.org\/10.1111\/his.12796","journal-title":"Histopathology"},{"key":"4895_CR28","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1038\/s41467-022-30573-4","volume":"13","author":"CA Rebbeck","year":"2022","unstructured":"Rebbeck CA, Xian J, Bornel\u00f6v S, Geradts J, Hobeika A, Geiger H, Alvarez JF, Rozhkova E, Nicholls A, Robine N, Lyerly HK, Hannon GJ (2022) Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma. Nat Commun 13:3399. https:\/\/doi.org\/10.1038\/s41467-022-30573-4","journal-title":"Nat Commun"},{"key":"4895_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10552-015-0696-z","volume":"27","author":"M Ruszczyk","year":"2016","unstructured":"Ruszczyk M, Zirpoli G, Kumar S, Bandera EV, Bovbjerg DH, Jandorf L, Khoury T, Hwang H, Ciupak G, Pawlish K, Schedin P, Masso-Welch P, Ambrosone CB, Hong CC (2016) Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses. Cancer Causes Control 27:183\u2013198. https:\/\/doi.org\/10.1007\/s10552-015-0696-z","journal-title":"Cancer Causes Control"},{"key":"4895_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1245\/s10434-006-9231-5","volume":"14","author":"S Sarp","year":"2007","unstructured":"Sarp S, Fioretta G, Verkooijen HM, Vlastos G, Rapiti E, Schubert H, Sappino AP, Bouchardy C (2007) Tumor location of the lower-inner quadrant is associated with an impaired survival for women with early-stage breast cancer. Ann Surg Oncol 14:1031\u20131039. https:\/\/doi.org\/10.1245\/s10434-006-9231-5","journal-title":"Ann Surg Oncol"},{"key":"4895_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"4895_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1758834012475152","volume":"5","author":"J Stagg","year":"2013","unstructured":"Stagg J, Allard B (2013) Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol 5:169\u2013181. https:\/\/doi.org\/10.1177\/1758834012475152","journal-title":"Ther Adv Med Oncol"},{"key":"4895_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4021\/wjon738w","volume":"4","author":"K Tariq","year":"2013","unstructured":"Tariq K, Rana F (2013) TNBC vs. Non-TNBC: a five-year retrospective review of differences in mean age, family history, smoking history and stage at diagnosis at an Inner City University Program. World J Oncol 4:241\u2013247. https:\/\/doi.org\/10.4021\/wjon738w","journal-title":"World J Oncol"},{"key":"4895_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jclinpath-2012-201428","volume":"66","author":"AA Thike","year":"2013","unstructured":"Thike AA, Iqbal J, Cheok PY, Tse GM, Tan PH (2013) Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. J Clin Pathol 66:665\u2013670. https:\/\/doi.org\/10.1136\/jclinpath-2012-201428","journal-title":"J Clin Pathol"},{"key":"4895_CR35","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.bjc.6605655","volume":"102","author":"H Wong","year":"2010","unstructured":"Wong H, Lau S, Yau T, Cheung P, Epstein RJ (2010) Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer 102:1391\u20131396. https:\/\/doi.org\/10.1038\/sj.bjc.6605655","journal-title":"Br J Cancer"},{"key":"4895_CR36","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1007\/s12032-011-0082-y","volume":"29","author":"H Wong","year":"2012","unstructured":"Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, Liang R, Epstein RJ, Yau T (2012) Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. Med Oncol 29:1536\u20131542. https:\/\/doi.org\/10.1007\/s12032-011-0082-y","journal-title":"Med Oncol"},{"key":"4895_CR37","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3389\/fonc.2019.01424","volume":"9","author":"LN Yu","year":"2019","unstructured":"Yu LN, Liu Z, Tian Y, Zhao PP, Hua X (2019) FAP-a and GOLPH3 are hallmarks of DCIS progression to invasive breast cancer. Front Oncol 9:1424. https:\/\/doi.org\/10.3389\/fonc.2019.01424","journal-title":"Front Oncol"},{"key":"4895_CR38","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41416-020-01212-w","volume":"124","author":"Y Zeng","year":"2021","unstructured":"Zeng Y, Gao W, Chen X, Shen K (2021) Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component. Br J Cancer 124:975\u2013981. https:\/\/doi.org\/10.1038\/s41416-020-01212-w","journal-title":"Br J Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04895-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:07:44Z","timestamp":1693300064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04895-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,24]]},"references-count":38,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["4895"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04895-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,24]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of our institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}